Chemistry:PF-00446687

From HandWiki
Revision as of 04:01, 6 February 2024 by S.Timg (talk | contribs) (fixing)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Experimental erectile dysfunction drug
PF-00446687
PF-00446687 structure.png
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC28H36F2N2O2
Molar mass470.593 g·mol−1
3D model (JSmol)

PF-00446687 is a drug developed by Pfizer for the treatment of erectile dysfunction, which is a non-peptide agonist selective for the melanocortin receptor subtype MC4. It was found to be active in preliminary human trials, with the 200mg dose being of similar effectiveness to 100mg sildenafil, though lower doses were ineffective.

Research

While it is unclear whether PF-00446687 itself will be potent and effective enough to be developed for medical use, it has demonstrated that selectively targeting the MC4 subtype can produce similar aphrodisiac effects to older non-selective peptide-based melanocortin receptor agonists like melanotan II and bremelanotide, without the side effects caused by action at the other melanocortin receptor subtypes.[1][2]

See also

References

  1. Calabrese A, Fradet D, Hepworth D, Lansdell M, "Pharmaceutically active compounds.", US patent 7649002, published 11 August 2005, assigned to Pfizer Inc
  2. "Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans". Journal of Medicinal Chemistry 53 (8): 3183–97. April 2010. doi:10.1021/jm9017866. PMID 20329799. 

External links

{{Navbox

| name = Sexual dysfunction pharmacotherapies
| title = Sexual dysfunction pharmacotherapies
| state = autocollapse
| bodyclass = hlist
| listclass = hlist
| group1 = Dopamine agonists
| list1 =
| group2 = Melanocortin agonists
| list2 =
| group3 = PDE5 inhibitors
| list3 =
| group4 = Sex steroids
| list4 =
| group5 = Others
| list5 =
| below =

}}